REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa